article

1. Metabolic tumor volume response after bridging therapy determines chimeric antigen receptor T-cell outcomes in large B cell lymphoma..  Clinical cancer research : an official journal of the American Association for Cancer Research.  2024
2. Subsequent Malignancies After CD19-Targeted Chimeric Antigen Receptor T Cells in Patients With Lymphoma..  Transplantation and cellular therapy.  2024
3. CNS Bridging Radiotherapy Achieves Rapid Cytoreduction Prior to CAR T Cell Therapy for Aggressive B-Cell Lymphoma..  Blood advances.  2024
4. Atrial arrhythmias following CAR-chimeric antigen receptor T-cell therapy: Incidence, risk factors and biomarker profile..  British journal of haematology.  2024
5. Transplantation-Associated Altered Mentation and Encephalopathy: A New Classification for Acute Neurocognitive Changes Associated with Hematopoietic Cell Transplantation from the ASTCT Committee on Practice Guidelines..  Transplantation and cellular therapy.  30:646-662. 2024
6. BEAM versus pharmacokinetics-directed BuCyVP16 conditioning for patients with peripheral T-cell lymphoma undergoing high-dose therapy with autologous hematopoietic cell transplantation..  American journal of hematology.  99:1180-1183. 2024
7. Cellular therapies in older adults with hematological malignancies: A case-based, state-of-the-art review..  Journal of geriatric oncology.  15:-. 2024
8. Transplantation and Cellular Therapy for Older Adults-The MSK Approach..  Current hematologic malignancy reports.  19:82-91. 2024
9. Prospective analysis to determine barriers to allogeneic hematopoietic cell transplantation in patients with acute leukemia..  American journal of hematology.  98:1869-1876. 2023
10. The Simplified Comorbidity Index predicts non-relapse mortality in reduced-intensity conditioning allogeneic haematopoietic cell transplantation..  British journal of haematology.  203:840-851. 2023
11. Analysis of Disparities in Time to Allogeneic Transplantation in Adults with Acute Myelogenous Leukemia..  Blood advances.  7:3824-3833. 2023
12. Prospective Geriatric Assessment and Geriatric Consultation in CAR T-cell Therapy for Older Lymphoma Patients..  Blood advances.  7:3501-3505. 2023
13. CD19 CAR T-cell therapy and prophylactic anakinra in relapsed or refractory lymphoma: phase 2 trial interim results..  Nature medicine.  29:1710-1717. 2023
14. Lack of disease control remains a major barrier to transplant for older patients with AML..  Bone marrow transplantation.  58:1054-1056. 2023
15. Older Adults With Newly Diagnosed AML: Hot Topics for the Practicing Clinician..  American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting.  -. 2023
16. The Transplant Ecosystem: A New Concept to Improve Access and Outcomes for Older Allogeneic Hematopoietic Cell Patients..  Transplantation and cellular therapy.  29:632.e1-632.e10. 2023
17. Open-Label, Pilot Study of Romiplostim for Thrombocytopenia After Autologous Hematopoietic Cell Transplantation..  Blood advances.  7:1536-1544. 2023
18. Characteristics of Distress and Support Group Participation in Caregivers of Older Allogeneic Hematopoietic Cell Transplantation Patients: A Single Institution Retrospective Review..  Journal of the advanced practitioner in oncology.  14:127-137. 2023
19. Bridging Radiation Rapidly and Effectively Cytoreduces High Risk Relapsed/Refractory Aggressive B-Cell Lymphomas Prior to Chimeric Antigen Receptor T-Cell Therapy..  Transplantation and cellular therapy.  29:259.e1-259.e10. 2022
20. Allogeneic Transplantation for Older Patients with Acute Myeloid Leukemia: The Dawn of a New Era..  Transplantation and cellular therapy.  28:793-794. 2022
21. Outcomes of first therapy after CD19-CAR-T treatment failure in large B-cell lymphoma..  Leukemia.  37:154-163. 2022
22. Impact of pre-transplant induction and consolidation cycles on AML allogeneic transplant outcomes: a CIBMTR analysis in 3113 AML patients..  Leukemia.  37:1006-1017. 2022
23. Racial Disparities in Access to Alternative Donor Allografts Persist in the Era of "Donors for All"..  Blood advances.  6:5625-5629. 2022
24. Vitamin D Insufficiency and Clinical Outcomes with Chimeric Antigen Receptor T-Cell Therapy in Large B-cell Lymphoma..  Transplantation and cellular therapy.  28:751.e1-751.e7. 2022
25. Activity of AZD7442 (tixagevimab-cilgavimab) against Omicron SARS-CoV-2 in patients with hematologic malignancies..  Cancer cell.  40:590-591. 2022
26. Prephase rituximab/prednisone therapy and aging-related, pro-inflammatory cytokine milieu in older, vulnerable patients with newly diagnosed diffuse large B-cell lymphoma.  Haematologica.  107:1144-1152. 2022
27. The Simplified Comorbidity Index: a new tool for prediction of nonrelapse mortality in allo-HCT..  Blood advances.  6:1525-1535. 2022
28. Allogeneic hematopoietic cell transplantation for older patients..  Hematology. American Society of Hematology. Education Program.  2021:254-263. 2021
29. TP53.  Journal of clinical oncology : official journal of the American Society of Clinical Oncology.  40:369-381. 2021
30. Hematopoietic Cell Transplantation is Feasible in Patients with Prior COVID-19 Infection..  Transplantation and cellular therapy.  28:55.e1-55.e5. 2021
31. Relapse after Allogeneic Stem Cell Transplantation of Acute Myelogenous Leukemia and Myelodysplastic Syndrome and the Importance of Second Cellular Therapy..  Transplantation and cellular therapy.  27:771.e1-771.e10. 2021
32. Immune Reconstitution in the Aging Host: Opportunities for Mechanism-Based Therapy in Allogeneic Hematopoietic Cell Transplantation..  Frontiers in immunology.  -. 2021
33. Impact of depth of clinical response on outcomes of acute myeloid leukemia patients in first complete remission who undergo allogeneic hematopoietic cell transplantation..  Bone marrow transplantation.  56:2108-2117. 2021
34. Breaking the Age Barrier: Physicians' Perceptions of Candidacy for Allogeneic Hematopoietic Cell Transplantation in Older Adults..  Transplantation and cellular therapy.  27:617.e1-617.e7. 2021
35. Cellular Therapy During COVID-19: Lessons Learned and Preparing for Subsequent Waves..  Transplantation and cellular therapy.  27:438.e1-438.e6. 2021
36. Impact and safety of chimeric antigen receptor T-cell therapy in older, vulnerable patients with relapsed/refractory large B-cell lymphoma..  Haematologica.  106:255-258. 2021
37. Outcomes in patients with DLBCL treated with commercial CAR T cells compared with alternate therapies..  Blood advances.  4:4669-4678. 2020
38. Geriatric syndromes in 2-year, progression-free survivors among older recipients of allogeneic hematopoietic cell transplantation..  Bone marrow transplantation.  56:289-292. 2020
39. Geriatric assessment in older alloHCT recipients: association of functional and cognitive impairment with outcomes..  Blood advances.  4:2810-2820. 2020
40. Impact of allogeneic hematopoietic cell transplantation on immune evasive mechanisms in relapsed refractory large B-cell lymphoma..  Bone marrow transplantation.  55:2331-2334. 2020
41. The geriatric syndrome of sarcopenia impacts allogeneic hematopoietic cell transplantation outcomes in older lymphoma patients..  Leukemia & lymphoma.  61:1833-1841. 2020
42. Characteristics and Impact of Post-Transplant Interdisciplinary Palliative Care Consultation in Older Allogeneic Hematopoietic Cell Transplant Recipients..  Journal of palliative medicine.  23:1653-1657. 2020
43. Microbiota as Predictor of Mortality in Allogeneic Hematopoietic-Cell Transplantation..  The New England journal of medicine.  382:822-834. 2020
44. Evidence-Based Minireview: Longitudinal geriatric assessment in quality care for older patients with hematologic malignancies..  Hematology. American Society of Hematology. Education Program.  2019:59-62. 2019
45. Impact of geriatric vulnerabilities on allogeneic hematopoietic cell transplantation outcomes in older patients with hematologic malignancies..  Bone marrow transplantation.  55:157-164. 2019
46. Hematopoietic-cell transplantation for lymphoma in the era of genetically engineered cellular therapy: it's not quite time to scrap the old vehicle for the new car..  Current opinion in hematology.  26:288-293. 2019
47. Feasibility of a patient-reported, electronic geriatric assessment tool in hematopoietic cell transplantation - a single institution pilot study..  Leukemia & lymphoma.  60:3308-3311. 2019
48. Burden and impact of multifactorial geriatric syndromes in allogeneic hematopoietic cell transplantation for older adults..  Blood advances.  3:12-20. 2019
49. Allogeneic haematopoietic cell transplantation impacts on outcomes of mantle cell lymphoma with TP53 alterations..  British journal of haematology.  184:1006-1010. 2018
50. End-of-life care for older AML patients relapsing after allogeneic stem cell transplant at a dedicated cancer center..  Bone marrow transplantation.  54:700-706. 2018
51. Pretransplant comprehensive geriatric assessment in hematopoietic cell transplantation: a single center experience..  Bone marrow transplantation.  53:1184-1187. 2018
52. Therapeutic Anticoagulation in Patients with Primary Brain Tumors or Secondary Brain Metastasis..  The oncologist.  23:468-473. 2017
53. Potentially inappropriate medication use in elderly non-Hodgkin lymphoma patients is associated with reduced survival and increased toxicities..  British journal of haematology.  180:267-270. 2017
54. Role of anthracycline and comprehensive geriatric assessment for elderly patients with diffuse large B-cell lymphoma..  Blood.  130:2180-2185. 2017
55. PEComa with Transcription Factor E3 Overexpression: A Diagnostic and Therapeutic Challenge..  Case reports in oncology.  10:531-533. 2017
56. Checkpoint Inhibition in Hodgkin Lymphoma: Saving the Best for Last?.  Oncology (Williston Park, N.Y.).  30:914-20. 2016
57. Development of highly aggressive mantle cell lymphoma after sofosbuvir treatment of hepatitis C..  Blood cancer journal.  6:-. 2016
58. Commentary on "Primary Care Providers' Comfort Levels in Caring for Patients With Sickle Cell Disease"..  Southern medical journal.  108:537-8. 2015
59. A Mixed-Methods Study of Pain-related Quality of Life in Sickle Cell Vaso-Occlusive Crises..  Hemoglobin.  39:305-9. 2015
60. A novel role for microphthalmia-associated transcription factor-regulated pigment epithelium-derived factor during melanoma progression..  The American journal of pathology.  185:252-65. 2014
61. A road less traveled..  Kidney international.  86:-. 2014
62. Quality Assessment of Acute Inpatient Pain Management in an Academic Health Center..  The American journal of hospice & palliative care.  33:16-9. 2014
63. Paraneoplastic thrombocytosis: the secrets of tumor self-promotion..  Blood.  124:184-7. 2014
64. The Barriers to High-Quality Inpatient Pain Management: A Qualitative Study..  The American journal of hospice & palliative care.  32:594-9. 2014
65. The sentinel hospitalization and the role of palliative care..  Journal of hospital medicine.  9:320-3. 2014
66. The role of palliative care in medical education..  Annals of internal medicine.  159:848-9. 2013
67. Silence..  Academic medicine : journal of the Association of American Medical Colleges.  88:-. 2013
68. Paraneoplastic autoimmunity associated with testicular myeloid sarcoma and chronic myelomonocytic leukemia..  Case reports in hematology.  -. 2013
69. Anemia in general medical inpatients prolongs length of stay and increases 30-day unplanned readmission rate..  Southern medical journal.  106:316-20. 2013
70. Allogeneic Hematopoietic Cell Transplantation for Therapy-Related Myeloid Leukemia following Orthotopic Cardiac Transplantation..  Case reports in hematology.  -. 2013
71. Back to basics..  The clinical teacher.  10:56-7. 2013
72. Away from home..  Journal of palliative medicine.  15:1392-3. 2012
73. Commentary on "relation between prefracture characteristics and perioperative complications in the elderly adult patient with hip fracture"..  Southern medical journal.  105:311-2. 2012
74. A mysterious stroke in a colon cancer patient..  QJM : monthly journal of the Association of Physicians.  107:919-22. 2012
75. Dyspnea in palliative care: expanding the role of corticosteroids..  Journal of palliative medicine.  15:834-7. 2012
76. My very first narcotics prescription..  Journal of palliative medicine.  14:1178-9. 2011
77. Hypoxia-induced transcriptional repression of the melanoma-associated oncogene MITF..  Proceedings of the National Academy of Sciences of the United States of America.  108:E924-33. 2011
78. An unusual cause of chest pain: Mycobacterium avium complex and the immune reconstitution inflammatory syndrome..  Journal of hospital medicine.  6:309-11. 2010
79. Lenalidomide for the treatment of cryoglobulinemia and undifferentiated spondyloarthropathy in a patient with multiple myeloma..  Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases.  16:90-1. 2010
80. Transcriptional regulation in acute promyelocytic leukemia..  Oncogene.  20:7204-15. 2001
81. Acquisition of oncogenic potential by RAR chimeras in acute promyelocytic leukemia through formation of homodimers..  Molecular cell.  5:821-30. 2000
82. Constitutive activation of transcription and binding of coactivator by estrogen-related receptors 1 and 2..  Molecular endocrinology (Baltimore, Md.).  13:2151-62. 1999
83. Regulation of hormone-induced histone hyperacetylation and gene activation via acetylation of an acetylase..  Cell.  98:675-86. 1999
84. Molecular genetics of acute promyelocytic leukemia..  Trends in genetics : TIG.  15:179-84. 1999
85. The LAZ3(BCL-6) oncoprotein recruits a SMRT/mSIN3A/histone deacetylase containing complex to mediate transcriptional repression..  Nucleic acids research.  26:4645-51. 1998
86. Role of the histone deacetylase complex in acute promyelocytic leukaemia..  Nature.  391:811-4. 1998
87. The transcriptional basis of steroid physiology..  Cold Spring Harbor symposia on quantitative biology.  577-85. 1998
88. Corepressor SMRT binds the BTB/POZ repressing domain of the LAZ3/BCL6 oncoprotein..  Proceedings of the National Academy of Sciences of the United States of America.  94:10762-7. 1997
89. Nuclear receptor coactivator ACTR is a novel histone acetyltransferase and forms a multimeric activation complex with P/CAF and CBP/p300..  Cell.  90:569-80. 1997
90. Nuclear receptor repression mediated by a complex containing SMRT, mSin3A, and histone deacetylase..  Cell.  89:373-80. 1997
91. Role of calf RTH-1 nuclease in removal of 5'-ribonucleotides during Okazaki fragment processing..  Biochemistry.  35:9266-77. 1996